Patton Albertson Miller Group LLC Decreases Position in Bristol-Myers Squibb (NYSE:BMY)

Patton Albertson Miller Group LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,101 shares of the biopharmaceutical company’s stock after selling 1,112 shares during the period. Patton Albertson Miller Group LLC’s holdings in Bristol-Myers Squibb were worth $364,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Bristol-Myers Squibb by 3.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 463,064 shares of the biopharmaceutical company’s stock valued at $26,876,000 after buying an additional 13,562 shares during the period. Park Avenue Securities LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.1% during the third quarter. Park Avenue Securities LLC now owns 50,800 shares of the biopharmaceutical company’s stock worth $2,948,000 after purchasing an additional 1,063 shares during the period. Gratus Capital LLC grew its stake in shares of Bristol-Myers Squibb by 7.2% in the third quarter. Gratus Capital LLC now owns 7,284 shares of the biopharmaceutical company’s stock worth $423,000 after purchasing an additional 491 shares during the last quarter. Smith Salley & Associates increased its holdings in Bristol-Myers Squibb by 7.3% during the 3rd quarter. Smith Salley & Associates now owns 13,466 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 917 shares during the period. Finally, TIAA Trust National Association bought a new position in Bristol-Myers Squibb during the 3rd quarter valued at approximately $8,023,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Up 2.5 %

Bristol-Myers Squibb stock traded up $1.08 during trading hours on Thursday, hitting $44.75. The stock had a trading volume of 10,774,480 shares, compared to its average volume of 15,686,079. The stock’s 50-day moving average price is $49.96 and its 200-day moving average price is $50.43. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a market capitalization of $90.71 billion, a P/E ratio of -14.43, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 EPS. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.36%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.